GlassScriptPhysician profile
Anthony Delicce
NPI 1295362465
$5,433.52
in general payments reported to CMS, 2019-2025
27 companies · $3,102 in 2025
The $3,102 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $305 · 2024: $2,026 · 2025: $3,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,082 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,081.97 |
| Education | $351.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,222.11 | 2024-2025 | Ensite, Optis, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $443.41 | 2023-2025 | Farxiga, Lokelma |
| Medtronic, INC. | $365.68 | 2024-2025 | Corevalve Evolut R, Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan |
| Amgen INC. | $365.15 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $299.28 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $291.22 | 2025 | Lifevest |
| Shockwave Medical, INC | $276.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $259.91 | 2024-2025 | Camzyos |
| Abiomed | $241.17 | 2024-2025 | Impella |
| Heartflow, INC. | $227.40 | 2025 | |
| Chiesi USA, INC. | $222.35 | 2023-2025 | Kengreal, Cleviprex |
| Pfizer INC. | $199.69 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.34 | 2025 | Jardiance |
| Boston Scientific Corporation | $125.40 | 2025 | Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $124.77 | 2024 | Winrevair |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $123.39 | 2024 | Amvia Edge |
| Regeneron Healthcare Solutions, INC. | $117.76 | 2024 | Dupixent |
| Kestra Medical Technology Services, INC. | $84.83 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $79.25 | 2024-2025 | |
| Tactile Systems Technology INC | $53.76 | 2025 | Nimbl, Flexitouch Plus |
| Terumo Medical Corporation | $47.78 | 2023-2025 | Glidewire, Progreat, Metacross Otw |
| Endotronix, INC. | $36.17 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Actelion Pharmaceuticals US, INC. | $23.88 | 2025 | |
| Becton, Dickinson and Company | $19.08 | 2025 | |
| Teleflex LLC | $18.69 | 2025 | Chocolate |
| Esperion Therapeutics, INC. | $16.29 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.88 | 2025 | Tryvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Delicce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.